Centrally-Linked Longitudinal Peripheral Biomarkers of Alzheimer’s Disease (CLEAR-AD)

What is the purpose of this study?

The CLEAR-AD initiative is working to advance personalized medicine for Alzheimer’s disease and related dementias. Researchers collect and study information such as brain scans, genes, proteins, and other biological markers to see how these factors interact over time and affect disease onset, progression, and treatment response. Led by Mayo Clinic Florida and Indiana University with national and international partners, CLEAR-AD aims to develop more accurate, personalized ways to diagnose and treat Alzheimer’s disease.

Who is a qualifying participant?

Participants in the CLEAR-AD study enroll in the Mayo Clinic ADRC and complete all ADRC procedures. The blood samples collected in ADRC are then shared with CLEAR AD investigators to find simple, reliable blood tests that can help detect Alzheimer’s disease earlier and more accurately.